alpha-aminopyridine has been researched along with ecallantide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akbari, P; Bryant, J; Gibson, G; Holsworth, D; Kolte, D; Shariat-Madar, Z; Wang, J | 1 |
| Bryant, JW; Gibson, GW; Kolte, D; Shariat-Madar, Z; Wang, J | 1 |
2 other study(ies) available for alpha-aminopyridine and ecallantide
| Article | Year |
|---|---|
Biochemical characterization of a novel high-affinity and specific plasma kallikrein inhibitor.
Topics: Aminobenzoates; Aminopyridines; Animals; Bradykinin; Cells, Cultured; Endothelial Cells; Enzyme Inhibitors; Epoprostenol; Humans; Inflammation; Kinetics; Kininogen, High-Molecular-Weight; Lipopolysaccharides; Muscle Contraction; Nitric Oxide; Phenylephrine; Plasma Kallikrein; Rats; Signal Transduction; Substrate Specificity | 2011 |
PF-04886847 (an inhibitor of plasma kallikrein) attenuates inflammatory mediators and activation of blood coagulation in rat model of lipopolysaccharide (LPS)-induced sepsis.
Topics: Aminobenzoates; Aminopyridines; Animals; Blood Coagulation; Disease Models, Animal; Disseminated Intravascular Coagulation; Dose-Response Relationship, Drug; Inflammation Mediators; Lipopolysaccharides; Male; Plasma Kallikrein; Rabbits; Rats; Rats, Sprague-Dawley; Respiratory Distress Syndrome; Sepsis; Thrombosis | 2012 |